Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Hemab Therapeutics Holdings, Inc. has successfully completed its initial public offering (IPO), raising approximately $346.7 million through the sale of 19,262,500 shares of common stock at a price of $18.00 per share. The offering, which included an additional 2,512,500 shares from underwriters exercising their option to purchase more shares, marks a significant milestone for the clinical-stage biotechnology company. Hemab's common stock began trading on the Nasdaq Global Select Market under the ticker symbol 'COAG' on May 1, 2026.

Founded with the mission to develop innovative therapies for blood coagulation disorders, Hemab Therapeutics is focused on addressing critical gaps in the treatment landscape for patients suffering from serious bleeding and thrombotic diseases. The company is advancing a portfolio of therapies, including sutacimig (HMB-001), a bispecific antibody aimed at treating Glanzmann thrombasthenia and Factor VII deficiency, as well as HMB-002, a monovalent antibody for Von Willebrand Disease. These therapies are designed to enhance patient outcomes and improve quality of life for individuals affected by these conditions.

The IPO comes at a time when the biotechnology sector is witnessing increased investor interest, particularly in companies that are developing specialized treatments for rare diseases. Hemab’s successful capital raise will provide the necessary funding to advance its clinical programs and expand its research initiatives. The involvement of prominent financial institutions, including Goldman Sachs & Co. LLC, Jefferies, and Evercore ISI as joint book-running managers, underscores the confidence in Hemab's strategic direction and the potential of its therapeutic pipeline.

As the biotechnology landscape continues to evolve, Hemab's entry into the public markets reflects broader trends of increased capital availability for innovative health solutions. The successful IPO could pave the way for other clinical-stage biotech firms to pursue similar routes to access capital and accelerate their growth trajectories. With a focus on developing groundbreaking therapies for coagulation disorders, Hemab Therapeutics is well-positioned to contribute to advancements in the field while also addressing significant unmet medical needs.

Overall, the completion of Hemab's IPO not only enhances its financial standing but also signals a growing appetite among investors for companies that are poised to make a meaningful impact in the healthcare sector. As the company progresses with its clinical development programs, it will be closely watched by market participants for its ability to deliver on its promises and drive shareholder value in the coming years.